News

head uk2

Respirators with chitosan nanoparticles as protection against SARS-CoV-2 infection

In the current corona pandemic, the protection of medical personnel who have contact with Covid-19 infected patients is important, also to ensure stability of the health care services. The personal protective equipment of hospital staff includes particle filtering respiratory masks. From early 2021, a clinical study will be conducted to investigate the protective effect of a new type of respirator with a filter element containing chitosan nanoparticles in Brazil. More about this study and other current clinical studies with chitosan in this article.

Tags: nanoparticles, Klinische Studie, Corona, SARS-CoV-2

Planned clinical study testing the effectiveness of a novel respirator with chitosan nanoparticles against SARS-CoV-2 infection:

The use of nanomaterials in respiratory masks could reduce the permeability of particles and increase the filtering performance against bacteria and viruses. The positively charged biopolymer chitosan has virucidal activity against several virus types, including coronavirus serotypes. The efficacy of a novel respirator with a filter element containing chitosan nanoparticles (called VESTA) will be investigated in comparison to a conventional N95 respirator. The respirators will be tested on medical personnel working in a hospital environment.

The study will be conducted in two phases:

1) a randomized clinical pilot study with reduced sample (n=50)
2) controlled randomized clinical trial. This study will be conducted with healthcare professionals in contact with environments/patients infected with SARS-CoV-2 or working in hospital sectors with higher susceptibility to infection (emergency and intensive care units). The study participants will be monitored for 21 days and the respiratory masks will be morphologically characterized (virus amount and inactivation) after the end of the first hospital shift.

Primary outcome measures:

  • Incidence of laboratory-confirmed COVID-19 cases [time frame: 21 days].
    (number of infected professionals, confirmed by RT-PCR)
  • Ability of the filter element to inactivate SARS-Cov-2 [time frame: 24 hours].

Find more information here: ClinicalTrials.gov Identifier: NCT04490200

Other current clinical studies with applications using chitosan and chitosan derivatives are listed with title, disease, type of planned medical intervention/device, status and study location below (clinicaltrials.gov, accessed December 15, 2020).

Status Title Disease Type of planned medical intervention/device Study location
Recruiting Efficacy and Safety of Sericin and Chitosan Cream for Preventing and Limiting the Progressive of Pressure Sore Pressure Ulcer Other: sericin and chitosan cream Thailand
Recruiting Comparison of Triple Antibiotic Paste With Combination of Chitosan and Calcium Hydroxide as a Root Canal Disinfectant Periapical Abscess Drug: root canal treatment and intracanal medicament India
Not yet recruiting Effectiveness of a Novel Respirator With Chitosan Nanoparticles

Covid19

SARS-CoV Infection

Worker-Patient Transmission, Healthcare

Device: VESTA respirator

Device: Conventional N95 respirator  

Brazil
Not yet recruiting Evaluation of Antimicrobial Efficacy and Adaptability of Bioceramic Sealer Containing Nanoparticles Endodontic Disease Drug: bioceramic sealer -
Recruiting Combination of InnoSEAL Plus TR Band Compared to TR Band Alone

Radial Artery Occlusion

Hematoma

Device: InnoSEAL+TRB

Device: TRB alone

Pakistan
Recruiting        Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors Advanced Solid Tumors       

Drug: IP-001

Device: Thermal Ablation

Switzerland
Recruiting       
   
RAVE: Radial Artery Vascular Complication and Resource Utilization in Subjects Undergoing an Angiogram/PCI

Angiogram

Percutaneous Coronary Intervention

Device: RadAR EasyCLik plus ®-STF hemostatic pad

Device: TR BAND® Compression device plus ®-STF hemostatic pad

United States

Not yet recruiting Clinical and Radiographic Evaluation of Nano Silver Fluoride Versus Calcium Hydroxide in Indirect Pulp Treatment of Deep Carious Second Primary Molars, Randomized Clinical Trial Deep Caries

Drug: Nano Silver Fluoride

Drug: Calcium hydroxide

-
Not yet recruiting Efficacy and Safety of High Absorption Pad in Split-thickness Skin Graft Donor Site Wound  Disorder of Skin Donor Site

Device: high absorption pad for blood and pus

Device: commercial wound dressing

 Thailand
Not yet recruiting Superficial Partial-Thickness Burn Study Superficial Partial Thickness Burn

Device: Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser

Drug: Silver Sulfadiazine

United States
Recruiting Dentures Biofilm and Artificial Biofilm Substitute Biofilm Other: 12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it Germany

Would you also like to conduct (clinical) trials with chitosan or develop new therapeutics? Contact us, we will be happy to help you select suitable chitosans for your application. 

Congress and fairs

Meet us in person 2021:

  • EUCHIS, 2021
  • CPHI 2021
  • Medica 2021
  • Asia Pacific Chitin and Chitosan Symposium, 2021, South Korea

To arrange an appointment please contact Katja Richter via sales(at)medical-chitosan.com

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • sales@medical-chitosan.com

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.